SPC
MLYS icon

Sigma Planning Corp’s Mineralys Therapeutics MLYS Stock Holding History

Sigma Planning Corp’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,000
Closed -$871K – 1374
2025
Q4 		$871K Buy
+24,000
New +$962K 0.02% 585

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Sigma Planning Corp's MLYS Position: Q1 2026 in Review

Sigma Planning Corp sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 24,000 shares — an estimated $871K sold.

Sigma Planning Corp first reported a position in MLYS in Q4 2025 and held it in 1 quarter. The position peaked at $871K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Sigma Planning Corp reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sigma Planning Corp sold 24,000 Mineralys Therapeutics shares in Q1 2026, an estimated $871K.
  • Sigma Planning Corp first reported a position in Mineralys Therapeutics in Q4 2025 and held it in 1 quarter.
  • Sigma Planning Corp's Mineralys Therapeutics position peaked at $871K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.